Guangzhou Wanzheng Pharmaceutical

Guangzhou Wanzheng Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the development of innovative small molecule therapeutics. The company's research and development efforts are concentrated on addressing significant unmet medical needs in autoimmune diseases, metabolic disorders, and oncology. Its lead candidate, WZ-011, is a potent URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Additionally, the company is advancing WZ-001, a selective JAK inhibitor, for various inflammatory indications such as rheumatoid arthritis. Wanzheng Pharmaceutical aims to establish a robust pipeline of proprietary drugs through its integrated drug discovery platform and internal manufacturing capabilities. The company is strategically located in the Guangzhou Science City, benefiting from the regional biotech ecosystem.